Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation
Category
FP7 Project with U.S. partner
Short name and number
OPTIMALVAC (223126)
Area
Health
Description
A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on
Participating Countries
Belgium, Denmark, France, Spain, Sweden, The Netherlands, United Kingdom, United States and Switzerland.
Name of US Partner
PROGRAM FOR APPROPRIATE TECHNOLOGYIN HEALTH, United States Department of Health and Human Services,
Contact
STATENS SERUM INSTITUT (DK)